

# Pharmacokinetics of dexmedetomidine in elderly patients undergoing sedation after abdominal aortic surgery



Agnieszka Bienert (1) Pawel Wiczling (2) Justyna Mocarcka (1) Lukasz Zuranski (3)  
Malgorzata Nowicka (3) Roma Hartmann-Sobczynska (3) Marcin Holysz (4) Jan Matysiak (5)  
Agnieszka Klupczynska (5) Edmund Grzeskowiak (1) Pawel Sobczynski (3)



**1** Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Sw. Marii Magdaleny 14 Street, 61-861 Poznan, Poland **2** Department of Biopharmacy and Pharmacodynamics, Medical University of Gdansk, Hallera 107 Street, 80-416 Gdansk, Poland **3** Department of Anesthesiology, Intensive Therapy and Pain Treatment, Clinical Hospital, Poznan University of Medical Sciences, Długa 1/2 Street, 60-780 Poznan, Poland **4** Department of Biochemistry and Molecular Biology University of Medical Sciences, Ul. Świecickiego 6, 60-781 Poznań **5** Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6 Street, 60-780 Poznan, Poland

**Introduction:** Dexmedetomidine (DEX) is an  $\alpha_2$ -agonist which has been increasingly used for analgesedation. The aim of this study was to characterize the population pharmacokinetics (PK) of dexmedetomidine in patients undergoing sedation after abdominal aortic surgery and to investigate the potential benefits of individualization of drug dosing based on patients' characteristics including genetic polymorphism, cardiac index and other cardiovascular parameters.

**Results:** Concentration-time profiles of DEX were obtained from 11 patients. Duration of infusion was less than 24 hours in all patients (Table 1). The DEX PK was best described by a two-compartment model. The typical values of PK parameters were estimated as 53.4 L for the volume of the central compartment, 112 L for the volume of the peripheral compartment, 51.1 L/h (for a typical patient) for systemic clearance and 36.7 L/h for the distribution clearance. Those values are consistent with literature findings. We were unable to show any significant relationship between collected covariates and DEX PK.

Parameter, unit	Median [Range or Number]
Age, years	64.5 [61-79]
Weight, kg	74.5 [55-85]
Male/Female	11/1
Infusion Time, h	4.8 [3.7-8.4]
Total dose of dex, mg	0.28 [0.16-0.60]

**Table 1.** Demographic characterization of patients. Results are expressed as median or range.


Parameter [unit]	Description	$\theta$ , Estimate (%RSE) [Shrinkage]	Estimate, Bootstrap Median [5 <sup>th</sup> 95 <sup>th</sup> CI]
$\theta_{vc}$ [L]	Volume of central compartment	53.4 (19.5)	52.9 [19.5 – 79.9]
$\theta_{cl}$ [L/h]	Systemic clearance	51.1 (6.3)	50.3 [45.7 – 56.2]
$\theta_{vT}$ [L]	Volume of peripheral compartment	112 (16.4)	115 [88.6 – 152]
$\theta_Q$ [L/h]	Inter-compartmental clearance	36.7 (29.7)	35.4 [20.6 – 61.5]
<b>Between Subject Variability</b>			
$\omega^2_{vc}$ [%CV]	Inter-individual variability of $V_c$	0 FIX	-
$\omega^2_{cl}$ [%CV]	Inter-individual variability of $CL$	21.3 (29.7) [0.0]	20.0 [9.8 – 28.7]
$\omega^2_{vT}$ [%CV]	Inter-individual variability of $V_T$	44.4 (26.6) [2.5]	37.0 [12.8 – 54]
$\omega^2_Q$ [%CV]	Inter-individual variability of $Q$	58.3 (34.3) [10.7]	52.3 [3.0 – 81.7]
<b>Residual Error Model</b>			
$\sigma^2$ [%CV]	Proportional residual error variability	21.1 (11.6) [11.9]	21.2 [16.9 – 25.5]

**Table 2.** The parameter estimates of the final PK model of dexmedetomidine. The bootstrap estimates are given for comparison. 25 out of 1000 bootstrap runs terminated early. RSE denotes relative standard errors whereas CV coefficient of variation.


**Conclusion:** This study does not provide sufficient evidence to support the individualization of DEX dosing based on age, sex, body weight, Cardiac Index, genetic polymorphism and infusion duration.

This project was supported by the grant 2015/17/B/NZ7/03032 founded by Polish National Science Centre.


**Methods:** Dexmedetomidine (Dexdor, Orion Pharma Poland Sp. z o.o.) was administered by continuous intravenous infusion without a loading dose. The infusion was started at the rate of 0.7  $\mu\text{g}/\text{kg}/\text{h}$  and titrated to achieve the desired level of sedation according to the monitored bispectral index (BIS, Philips Medical Systems B.V, Netherlands). BIS values were kept between 60 and 80. Cardiac index (CI), a hemodynamic parameter related to cardiac output was measured and recorded by FloTrac System (Edwards Lifesciences, USA). Blood samples for DEX assay were collected daily during the infusion and at the selected time points after its termination. The DEX concentrations in the plasma were measured using LC-MS/MS method. The following covariates were examined to influence DEX PK: patients' age, sex, body weight, systolic and diastolic blood pressure, heart rate, cardiac index, infusion duration as well as CYP2C19, CYP1A2, CYP2A6, UGT1A4 and UGT2B genetic polymorphism. Non-linear mixed-effects modelling in NONMEM (Version 7.3.0, Icon Development Solutions, Ellicott City, MD, USA) was used to analyze the observed data.





**Figure 1.** The individual dexmedetomidine concentration-time profiles.



**Figure 2.** The VPC plots for dexmedetomidine PK. The VPC plots show the simulation-based 90% confidence intervals around the 10th, 50th, and 90th percentiles of the PK data in the form of blue (50<sup>th</sup>) and gray (10<sup>th</sup> and 90<sup>th</sup>) areas. The corresponding percentiles from the prediction corrected observed data are plotted in black color.




**Figure 3.** Relationship between body weight normalized clearance and volume of distribution at steady state versus age, body weight, infusion duration and sex for all patients in the study.



**Figure 4.** Relationship between body weight normalized clearance and volume of distribution at steady state haemodynamic parameters for all patients in the study.

**Figure 5.** Relationship between body weight normalized clearance and volume of distribution at steady state versus sex, CYP2C19\*2 and CYP2C19\*1 polymorphism. The figure consists of six scatter plots showing CL/BW (L/h/kg) and Vss/BW (L/kg) on the y-axis versus Male/Female, CYP2C19\*2, and CYP2C19\*1 on the x-axis. The plots show no significant correlation between these parameters and the variables on the x-axis.



**Figure 6.** Goodness-of-fit plots for the final dexmedetomidine PK model: the observed versus the population predicted responses, the observed versus the individual predicted responses, C, the conditional weighted residuals (CWRES) versus the individual predicted responses, and the CWRES versus time.